Pasithea Therapeutics Corp.
NCM: KTTALive Quote
📈 ZcoreAI Score
Our AI model analyzes Pasithea Therapeutics Corp.'s price action across multiple timeframes using regression channels and statistical scoring.
Get KTTA Z-Score →About Pasithea Therapeutics Corp.
Healthcare
Biotechnology
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
📊 Fundamental Analysis
Pasithea Therapeutics Corp. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -58.4%, which indicates that capital utilization is currently under pressure.
At a current price of $0.70, KTTA currently trades near the bottom of its 52-week range (12%), indicating potential value or weakness (Range: $0.28 - $3.79).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$17.46M
Trailing P/E
--
Forward P/E
-0.33
Beta (5Y)
0.25
52W High
$3.79
52W Low
$0.28
Avg Volume
316K
Day High
Day Low